BioTuesdays
Relypsa

HCW starts Relypsa at buy

H.C. Wainwright has initiated coverage of Relypsa (NASDAQ:RLYP) with a “buy” rating and price target of $63. The stock closed at $28.31 on Wednesday. “We believe [Relypsa’s] Veltassa is well positioned to address the...

OraSure Technologies

BTIG starts OraSure Technologies at buy

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...

Piper Jaffray

Piper Jaffray top healthcare picks for 2016

Each year, Piper Jaffray asks its analysts to provide the one name in their universe where they believe they have a differentiated opinion, high conviction and see catalysts ahead in the coming year.Piper Jaffray’s Top...

Titan Pharmaceuticals Logo

Roth ups Titan Pharma price target to $7.25

Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed at $4.92 on...

Can-Fite

HCW ups Can-Fite BioPharma price target to $6

H.C. Wainwright has raised its price target on “buy-rated” Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) to $6 from $4. The stock closed at $3.23 on Friday. “In our view, the company’s piclidenoson programs remain the...

GW Pharmaceuticals

Roth reinitiates coverage of GW Pharma at buy

Roth Capital Partners is reinitiating coverage of GW Pharmaceuticals (NASDAQ:GWPH) with a “buy” rating and 12-month target price of $130 per American Depository Share. The ADS closed at $84.90 on Friday GW is developing...

Stellar Biotechnologies

Maxim starts Stellar Biotechnologies at buy

Maxim Group has initiated coverage of Stellar Biotechnologies (NASDAQ:SBOT) with a “buy” rating and $17 price target. The stock closed at $7.48 on Monday. Stellar leverages its on-land aquaculture facilities to...

MAST Therapeutics

Maxim starts Mast Therapeutics at buy

Maxim Group has initiated coverage of Mast Therapeutics (NYSE:MSTX) with a “buy” rating and price target of $5. The stock closed at 42 cents on Wednesday. Mast’s vepoloxamer is in the pivotal Phase 3 EPIC study, with...

CorMedix

Rodman starts CorMedix at buy

Rodman & Renshaw has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and price target of $6.50. The stock closed at $2.48 on Wednesday. CorMedix is developing a novel catheter lock solution (CLS)...

novadaq

Wedbush ups Novadaq price target to $17

Wedbush Securities has raised its price target for “outperform-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to $17 from $15. The stock finished at $11.16 on Wednesday. “Novadaq is the leader in the rapidly growing...

Sophiris Bio Logo

Euro Pacific upgrades Sophiris Bio to buy

Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in...

Strongbridge Biopharma

Stifel starts Strongbridge Biopharma at buy

Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday. Strongbridge is an endocrinology-focused...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.